Discover 1,106 paid clinical trials in Salt Lake City, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
There are a wide variety of studies currently listed in Salt Lake City, focusing on conditions such as autism, celiac disease, and osteoporosis. The city's leading medical research institutions are actively recruiting participants, providing access to cutting-edge treatments and therapies for both healthy volunteers interested in paid clinical trials and individuals in need of studies for specific health conditions.
Filter
2
Filter results
Results: 1,106
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
for
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Location: Sandy City UT, Austin TX, Detroit MI, Morehead City NC,
Sponsor: DreaMed Diabetes
Sex: All
Age: 18 - 70+
Code: NCT07599982
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
for
Overweight, Obesity
Location: Sandy City UT, Ogden UT, Aurora CO, Albuquerque NM,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07282600
Phase 3, Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
for
Chronic Inducible Urticaria, Cold Urticaria,
Location: Sandy City UT, Boise ID, Scottsdale AZ, Napa CA,
Sponsor: Celldex Therapeutics
Sex: All
Age: 18+
Code: NCT07266402
Phase 3, Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
for
Clostridoides Difficile Associated Disease
Location: Salt Lake City UT, Shiprock NM, Chinle AZ, Gallup NM,
Sponsor: Pfizer
Sex: All
Age: 65+
Code: NCT07282665
Phase 3, Recruiting
SUMMIT RISE Study of Acute Ischemic Stroke Patients
for
Acute Ischemic Stroke
Location: West Jordan UT
Sponsor: Route 92 Medical, Inc.
Sex: All
Age: 18+
Code: NCT07436156
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
for
Non-alcoholic Fatty Liver Disease
Location: West Jordan UT, Arcadia CA, Covina CA, Van Nuys CA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70+
Code: NCT07221188
Phase 3, Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
for
Non-alcoholic Fatty Liver Disease
Location: West Jordan UT, Las Vegas NV, Colorado Springs CO,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70+
Code: NCT07221227
Phase 3, Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Location: West Jordan UT, Denver CO, Scottsdale AZ, Sacramento CA,
Sponsor: EyeBiotech Ltd.
Sex: All
Age: 18+
Code: NCT07205887
Phase 2, Recruiting
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities
for
Periprosthetic Joint Infections
Location: West Jordan UT, Los Angeles CA, Carrollton TX,
Sponsor: Elute, Inc.
Sex: All
Age: 22+
Code: NCT05361941
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
for
Obesity, Overweight
Location: South Jordan UT, Gulfport MS
Sponsor: Eli Lilly and Company
Sex: All
Age: 12 - 17
Code: NCT06672939
Phase 3, Recruiting
Study of DONQ52 in Active Celiac Disease
for
Celiac Disease
Location: West Jordan UT, Sandy City UT, Ogden UT, Clermont FL,
Sponsor: Chugai Pharmaceutical
Sex: All
Age: 18 - 70+
Code: NCT07239336
Phase 2, Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
for
Type 2 Diabetes, Cortisol Excess
Location: West Jordan UT, Boise ID, Las Vegas NV, Chandler AZ,
Sponsor: Sparrow Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07296484
Phase 2, Recruiting
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
for
Pneumococcal Disease
Location: West Jordan UT, Layton UT, Provo UT, Syracuse UT,
Sponsor: Pfizer
Sex: All
Age: 1 - 17
Code: NCT07660198
Phase 3, Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
for
Asthma
Location: West Jordan UT, Denver CO, Missoula MT, Albuquerque NM,
Sponsor: AstraZeneca
Sex: All
Age: 12 - 17
Code: NCT06307665
Phase 3, Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
for
Locally Advanced / Metastatic Solid Tumors
Location: West Valley City UT, Denver CO, Los Angeles CA,
Sponsor: Crescent Biopharma, Inc.
Sex: All
Age: 18+
Code: NCT07335497
Phase 1, Phase 2, Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
for
Viral Lung Infection and Acute Respiratory Failure
Location: Salt Lake City UT, Boise ID, Colorado Springs CO,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05624450
Phase 3, Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
for
Irritable Bowel Syndrome
Location: Sandy City UT, Ogden UT, Idaho Falls ID, Meridian ID,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70+
Code: NCT07519395
Phase 2, Recruiting
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
for
Atopic Dermatitis (AD), Eczema
Location: South Jordan UT, San Antonio TX, College Station TX,
Sponsor: Arcutis Biotherapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT07453602
Phase 1, Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
for
Hidradenitis Suppurativa (HS)
Location: South Jordan UT, Phoenix AZ, Spokane WA, Northridge CA,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT06855498
Phase 3, Recruiting
Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction